Meta-analysis Of Dedicated Renal Outcome Trials Assessing the Cardio-renal Efficacy of Sodium-Glucose Co-transporter-2 Inhibitors In Patients With Chronic Kidney Disease And Albuminuria

Chronic kidney disease (CKD) represents a frequent co-morbidity of type 2 diabetes mellitus (T2DM), affecting 30-50% of all patients, while diabetes is the leading cause of end-stage kidney disease (ESKD) worldwide.1,2 Vice versa, incidence rates of T2DM among patients with CKD are significantly higher compared to the general population.3 Sufficient glycemic control is required for all patients suffering from CKD and TDM; however, very strict control has been shown to increase all-cause mortality similarly to insufficient control.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research